The patent decision removes the worst-case scenario that Tecfidera will go generic in 2020-2023, says RBC's Michael Yee. With better visibility on Biogen's (BIIB +0.8%) largest drug franchise, the company becomes more attractive to a buyer, he adds.
Still awaited is the interference decision vs. Forward Pharma (FWP -2.5%), and Leerink's Jason Gerberry calls today's ruling a marginal positive for FWP. Should FWP win the case, it makes it more challenging for generics to invalidate the dosing patent in a later district court patent challenge.
Previously: Biogen up 1% on favorable patent decision (March 21)
Subscribe for full text news in your inbox